Bafna Pharmaceuticals Limited
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations
What Bafna files
- Others45
- Board Meeting11
- Important9
- Updates1
- QIP/Rights/Pref.1
- Credit Ratings1
Bafna Pharma announces its 31st Annual General Meeting will be held via video conference. The company has set book closure dates for shareholders to determine eligibility for the AGM and e-voting. Shareholders can participate remotely.
Bafna Pharmaceuticals has completed the sale of its manufacturing unit at Madhavaram, Chennai, to Navron Pharma for Rs. 1.45 Cr. The unit contributed minimally to revenue (0.08%) but had a net worth contribution of 1.55% as of March 31, 2025. The buyer is an independent party, and the deal is...
Bafna Pharmaceuticals Limited has informed the Exchange about the re-constitution of the Audit Committee, Nomination-Remuneration Committee of the Board w.e.f June 25, 2025
Bafna Pharmaceuticals has announced a board meeting to re-constitute its Nomination and Remuneration Committee, appointing Mrs. Ravichandran Chitra as chairperson alongside Mr. Palamadai Krishnan Sundaresan and Mrs. Akila Chintalapati Raju as members. No financial impact was indicated.
Bafna Pharmaceuticals has been recognized as the “Emerging Company of the Year in Healthcare” at the MSME Global Platinum Business Excellence Award, highlighting its impact in the sector. This recognition may enhance the company's reputation and boost investor confidence, although no direct financial implications were disclosed.